[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350585-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350585-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","omission-of-sentinel-lymph-node-biopsy-in-breast-cancer-a-real-world-validation-of-the-patient-populations-of-the-sound-and-insema-trials","Omission of Sentinel Lymph Node Biopsy in Breast Cancer - A Real-World Validation of the Patient Populations of the SOUND and INSEMA Trials","","Guidelines support omitting axillary surgery in breast cancer, yet the real-world representativeness of SOUND and INSEMA trial populations remains uncertain. A single-hospital cohort of consecutive early breast cancer patients (2010–2018) with clinically node-negative disease was assessed for eligibility using the trials’ inclusion criteria. Clinicopathologic characteristics were compared with published trial groups. SOUND eligibility broadly matched real-world patients, whereas INSEMA showed stronger selection toward biologically favorable tumors and underrepresentation of larger and more aggressive subtypes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/omission-of-sentinel-lymph-node-biopsy-in-breast-cancer-a-real-world-validation-of-the-patient-populations-of-the-sound-and-insema-trials/350585/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/omission-of-sentinel-lymph-node-biopsy-in-breast-cancer-a-real-world-validation-of-the-patient-populations-of-the-sound-and-insema-trials/350585.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about the SOUND and INSEMA trials?","Question",{"text":63,"@type":64},"It evaluates how well the SOUND and INSEMA eligibility criteria apply to unselected real-world patients, focusing on external validity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected and screened for trial eligibility in this real-world validation?",{"text":68,"@type":64},"Consecutive early breast cancer patients treated at a single university hospital (2010–2018) with clinically node-negative disease were included, and eligibility was determined using the trials’ inclusion criteria.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings comparing trial eligibility cohorts to real-world patients?",{"text":72,"@type":64},"SOUND-eligible patients were largely representative of real-world clinicopathologic characteristics, while INSEMA-eligible patients appeared more selected, with a higher share of biologically favorable tumors and underrepresentation of larger and more aggressive subtypes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350585,1790539233,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Journal of Surgical Oncology   \nRESEARCH ARTICLE   \nOmission of Sentinel Lymph Node Biopsy in Breast Cancer: A Real‐World Validation of the Patient Populations of the SOUND and INSEMA Trials  \nTia Puiras1 | Eeva Juhanoja1,2 | Anselm Tamminen1,3  \n1Faculty of Medicine, University of Turku, Turku, Finland | 2Department of Oncology, Turku University Hospital, Turku, Finland | 3Department of Plastic and General Surgery, Turku University Hospital, Turku, Finland  \nCorrespondence: Anselm Tamminen ([anselm.tamminen@utu.fi](anselm.tamminen@utu.fi))  \nReceived: 18 December 2025 | Revised: 22 March 2026 | Accepted: 1 April 2026  \nKeywords: axillary lymph node dissection | breast cancer | de‐escalation | sentinel lymph node biopsy | surgery  \nABSTRACT  \nBackground: Treatment guidelines recommending omission of axillary surgery in breast cancer are largely based on the SOUND and INSEMA trials. However, the extent to which their study populations represent real‐world patients remains unclear. We aimed to evaluate the real‐world applicability and external validity of these trial populations.  \nMaterials and Methods: All consecutive patients treated for early breast cancer at a single university hospital between 2010 and 2018 were included. Patients with clinically node‐negative disease were identified, and eligibility according to the SOUND and INSEMA inclusion criteria was determined. Clinicopathologic characteristics were compared between trial‐eligible real‐ world patients and published trial populations.  \nResults: A total of 2787 consecutive patients with clinically negative axilla were included; 71%(1982/2787) fulfilled the INSEMA and 52%(1461/2787) the SOUND trial eligibility criteria. Patients eligible in the SOUND trial were largely representative of real‐world patients in terms of clinicopathologic characteristics. In contrast, the INSEMA trial appeared more selected, with a higher proportion of biologically favorable tumors. Both trials predominantly included patients with small (\u003C 2 cm) luminal breast cancers. Patients with larger tumors and more aggressive subtypes were underrepresented. Conclusion: The SOUND and INSEMA eligibility criteria are broadly applicable to real‐world patients with small luminal breast cancers. However, differences between trial populations and real‐world patients highlight the need for careful consideration when applying SLNB omission beyond these lower‐risk subgroups.  \n1 | Introduction  \nBreast cancer is the most commonly diagnosed cancer among women with 2.3 million new cases in 2022, accounting for 23.8% of all cancer cases in females worldwide. It is the leading cause of cancer mortality in women with an estimated 666 000 deaths in 2022, accounting for 15.4% of all female cancer‐related deaths [1] .  \nThe nodal status of the axilla is an important prognostic factor for breast cancer. The pathological status of a sentinel lymph node  \n(SLN) is known to accurately represent the pathological nodal status in the axilla, and implementation of sentinel lymph node biopsy (SLNB) has revolutionized axillary staging [2]. SLNB has largely replaced ALND as the standard method for axillary staging in clinically node‐negative (cN0) breast cancer [3]. Studies have shown that in patients with a SLN negative breast cancer, ALND can be safely omitted without compromising overall survival or recurrence outcomes [4]. Furthermore, randomized clinical trials (RCTs) such as the ACOSOG Z0011 trial, AMAROS, and SENOMAC have demonstrated that selected  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . Journal of Surgical Oncology published by Wiley Periodicals LLC.  \nJournal of Surgical Oncology, 2026; 133:1007–1015 1007  \n[https://doi.org/10.1002/jso.70256](https://doi.org/10.1002/jso.70256)  \nSummary  \nThe SOUND and INSEMA trials support the omi","cbCaia85VUX4dyBs","https://ap.wps.com/l/cbCaia85VUX4dyBs","pdf",694781,"English","# Abstract\n## Background\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n## Rationale and external validity\n# Methods (Eligibility Assessment)\n## Patient selection and comparison","[{\"question\":\"What question does the study address about the SOUND and INSEMA trials?\",\"answer\":\"It evaluates how well the SOUND and INSEMA eligibility criteria apply to unselected real-world patients, focusing on external validity.\"},{\"question\":\"How were patients selected and screened for trial eligibility in this real-world validation?\",\"answer\":\"Consecutive early breast cancer patients treated at a single university hospital (2010–2018) with clinically node-negative disease were included, and eligibility was determined using the trials’ inclusion criteria.\"},{\"question\":\"What were the main findings comparing trial eligibility cohorts to real-world patients?\",\"answer\":\"SOUND-eligible patients were largely representative of real-world clinicopathologic characteristics, while INSEMA-eligible patients appeared more selected, with a higher share of biologically favorable tumors and underrepresentation of larger and more aggressive subtypes.\"}]","Omission of Sentinel Lymph Node Biopsy in Breast Cancer - A Real-World Validation of the Patient Populations of the SOUND and INSEMA Trials | PDF",1790089696,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5933be0c0064f9223a4c25261f43718.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc219132a9e88b3b426232bdb0cd9917.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7aa9821893cbf2c8e56e72bafaf27fb0.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6951aadf2d953f0a3bc690721902d2a6.webp",980,1287]